1、 CALSES P C,CRAWFORD J J,LILL J R,et al.Hippo pathway in cancer:Aberrant regulation and therapeutic opportunities[J].Trends Cancer,2019,5(5):297-307. CALSES P C,CRAWFORD J J,LILL J R,et al.Hippo pathway in cancer:Aberrant regulation and therapeutic opportunities[J].Trends Cancer,2019,5(5):297-307.
2、 WANG J,ZHOU M,ZHANG Q G,et al.Prognostic value of expression of nuclear factor kappa-B/p65 in non-GCB DLBCL patients[J].Oncotarget,2017,8(6):9708-9716. WANG J,ZHOU M,ZHANG Q G,et al.Prognostic value of expression of nuclear factor kappa-B/p65 in non-GCB DLBCL patients[J].Oncotarget,2017,8(6):9708-9716.
3、 VITOLO U,WITZIG T E,GASCOYNE R D,et al.ROBUST:First report of phase III randomized study of lenalidomide/R-CHOP(R2-CHOP)vs placebo/R-CHOP in previously untreated ABC-type diffuse large B-cell lymphoma[J].Hematol Oncol,2019,37(S2):36-37. VITOLO U,WITZIG T E,GASCOYNE R D,et al.ROBUST:First report of phase III randomized study of lenalidomide/R-CHOP(R2-CHOP)vs placebo/R-CHOP in previously untreated ABC-type diffuse large B-cell lymphoma[J].Hematol Oncol,2019,37(S2):36-37.
4、 DAVIES A,CUMMIN T E,BARRANS S,et al.Gene-expression profiling of bortezomib added to standard chemoimmunotherapy for diffuse large B-cell lymphoma(REMoDL-B):An open-label,randomised,phase 3 trial[J].Lancet Oncol,2019,20(5):649-662. DAVIES A,CUMMIN T E,BARRANS S,et al.Gene-expression profiling of bortezomib added to standard chemoimmunotherapy for diffuse large B-cell lymphoma(REMoDL-B):An open-label,randomised,phase 3 trial[J].Lancet Oncol,2019,20(5):649-662.
5、 KESHET R,ADLER J,RICARDO LAX I,et al.c-Abl antagonizes the YAP oncogenic function[J].Cell Death Differ,2015,22(6):935-945. KESHET R,ADLER J,RICARDO LAX I,et al.c-Abl antagonizes the YAP oncogenic function[J].Cell Death Differ,2015,22(6):935-945.
6、 OKAZAKI T,KAGEJI T,KUWAYAMA K,et al.Up-regulation of endogenous PML induced by a combination of interferon-beta and temozolomide enhances p73/YAP-mediated apoptosis in glioblastoma[J].Cancer Lett,2012,323(2):199-207. OKAZAKI T,KAGEJI T,KUWAYAMA K,et al.Up-regulation of endogenous PML induced by a combination of interferon-beta and temozolomide enhances p73/YAP-mediated apoptosis in glioblastoma[J].Cancer Lett,2012,323(2):199-207.
7、 KIM M K,JANG J W,BAE S C.DNA binding partners of YAP/TAZ[J].BMB Rep,2018,51(3):126-133. KIM M K,JANG J W,BAE S C.DNA binding partners of YAP/TAZ[J].BMB Rep,2018,51(3):126-133.
8、 BOUVIER C,MACAGNO N,NGUYEN Q,et al.Prognostic value of the Hippo pathway transcriptional coactivators YAP/TAZ and β1-integrin in conventional osteosarcoma[J].Oncotarget,2016,7(40):64702-64710. BOUVIER C,MACAGNO N,NGUYEN Q,et al.Prognostic value of the Hippo pathway transcriptional coactivators YAP/TAZ and β1-integrin in conventional osteosarcoma[J].Oncotarget,2016,7(40):64702-64710.
9、 ZHAO T,WANG Z,FANG J,et al.HTLV-1 activates YAP via NF-κB/p65 to promote oncogenesis[J].Proc Natl Acad Sci U S A,2022,119(9):e2115316119. ZHAO T,WANG Z,FANG J,et al.HTLV-1 activates YAP via NF-κB/p65 to promote oncogenesis[J].Proc Natl Acad Sci U S A,2022,119(9):e2115316119.
10、 CHANG T Y,WU C T,SHEU M L,et al.CARMA3 promotes colorectal cancer cell motility and cancer stemness via yap-mediated NF-κB activation[J].Cancers,2021,13(23):5946. CHANG T Y,WU C T,SHEU M L,et al.CARMA3 promotes colorectal cancer cell motility and cancer stemness via yap-mediated NF-κB activation[J].Cancers,2021,13(23):5946.
11、 GAO Y,YANG Y,YUAN F,et al.TNFα-YAP/p65-HK2 axis mediates breast cancer cell migration[J].Oncogenesis,2017,6(9):e383. GAO Y,YANG Y,YUAN F,et al.TNFα-YAP/p65-HK2 axis mediates breast cancer cell migration[J].Oncogenesis,2017,6(9):e383.
12、 CHEN R,ZHOU D,WANG L,et al.MYD88L265P and CD79B double mutations type(MCD type)of diffuse large B-cell lymphoma:mechanism,clinical characteristics,and targeted therapy[J].Ther Adv Hematol,2022(13):20406207211072839. CHEN R,ZHOU D,WANG L,et al.MYD88L265P and CD79B double mutations type(MCD type)of diffuse large B-cell lymphoma:mechanism,clinical characteristics,and targeted therapy[J].Ther Adv Hematol,2022(13):20406207211072839.
13、 ZHANG T,MA C,ZHANG Z,et al.NF-κB signaling in inflammation and cancer[J].MedComm,2021,2(4):618-653. ZHANG T,MA C,ZHANG Z,et al.NF-κB signaling in inflammation and cancer[J].MedComm,2021,2(4):618-653.
14、 TANIGUCHI K,KARIN M.NF-κB,inflammation,immunity and cancer:Coming of age[J].Nat Rev Immunol,2018,18(5):309-324. TANIGUCHI K,KARIN M.NF-κB,inflammation,immunity and cancer:Coming of age[J].Nat Rev Immunol,2018,18(5):309-324.
15、 KYRIAZOGLOU A,NTANASIS-STATHOPOULOS I,TERPOS E,et al.Emerging insights into the role of the hippo pathway in multiple myeloma and associated bone disease[J].Clin Lymphoma Myeloma Leuk,2020,20(2):57-62. KYRIAZOGLOU A,NTANASIS-STATHOPOULOS I,TERPOS E,et al.Emerging insights into the role of the hippo pathway in multiple myeloma and associated bone disease[J].Clin Lymphoma Myeloma Leuk,2020,20(2):57-62.
16、 MORIYAMA K,HORI T.BCR-ABL induces tyrosine phosphorylation of YAP leading to expression of Survivin and Cyclin D1 in chronic myeloid leukemia cells[J].Int J Hematol,2019,110(5):591-598. MORIYAMA K,HORI T.BCR-ABL induces tyrosine phosphorylation of YAP leading to expression of Survivin and Cyclin D1 in chronic myeloid leukemia cells[J].Int J Hematol,2019,110(5):591-598.
17、 HU X,ZHANG Y,YU H,et al.The role of YAP1 in survival prediction,immune modulation,and drug response:A pan-cancer perspective[J].Front Immunol,2022(13):1012173. HU X,ZHANG Y,YU H,et al.The role of YAP1 in survival prediction,immune modulation,and drug response:A pan-cancer perspective[J].Front Immunol,2022(13):1012173.
18、 KULKARNI A,CHANG M T,VISSERS J H A,et al.The hippo pathway as a driver of select human cancers[J].Trends Cancer,2020,6(9):781-796. KULKARNI A,CHANG M T,VISSERS J H A,et al.The hippo pathway as a driver of select human cancers[J].Trends Cancer,2020,6(9):781-796.
19、 MORIN R D,ASSOULINE S,ALCAIDE M,et al.Genetic landscapes of relapsed and refractory diffuse large B-Cell Lymphomas[J].Clin Cancer Res,2016,22(9):2290-2300. MORIN R D,ASSOULINE S,ALCAIDE M,et al.Genetic landscapes of relapsed and refractory diffuse large B-Cell Lymphomas[J].Clin Cancer Res,2016,22(9):2290-2300.
20、 CRUMP M,NEELAPU S S,FAROOQ U,et al.Outcomes in refractory diffuse large B-cell lymphoma:Results from the international SCHOLAR-1 study[J].2018,131(5):587-588. CRUMP M,NEELAPU S S,FAROOQ U,et al.Outcomes in refractory diffuse large B-cell lymphoma:Results from the international SCHOLAR-1 study[J].2018,131(5):587-588.
21、 THANDRA K C,BARSOUK A,SAGINALA K,et al.Epidemiology of non-hodgkin's lymphoma[J].Med Sci,2021,9(1):5. THANDRA K C,BARSOUK A,SAGINALA K,et al.Epidemiology of non-hodgkin's lymphoma[J].Med Sci,2021,9(1):5.
22、 SEHN L H,SALLES G.Diffuse large B-cell lymphoma[J].N Engl J Med,384(9):842-858. SEHN L H,SALLES G.Diffuse large B-cell lymphoma[J].N Engl J Med,384(9):842-858.
